A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Protocol No
NEPH-ALEXION-ALXN1210-202
Phase
II
Summary

This project is being done to test the safety and efficacy of ALXN1210 (ravulizamab) in individuals with IgaN or LN.

Description
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL